William Blair acted as financial advisor to Sartorius AG in connection with its acquisition of MatTek, a subsidiary of BICO Group AB. The transaction was signed on April 4, 2025, and closed on July 1, 2025.
About the Companies
Sartorius AG is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the group’s lab products and services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The bioprocess solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. The company is based in Göttingen, Germany and has a strong global reach with about 60 production and sales sites worldwide. Sartorius AG regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of roughly €3.4 billion. About 13,500 employees are working for customers around the globe.
MatTek is a leading developer and manufacturer of human cell-based microtissues and 3D models that accelerate drug development. The advanced cell models mimic the structure and function of human tissue and deliver more accurate, cost-effective, and reproducible results compared to traditional 2D cell cultures, while reducing the need for animal testing. The company employs more than 80 people at its headquarters in Ashland, Massachusetts, United States, and at its production site in Bratislava, Slovakia.
Learn more about our medical technology investment banking expertise.